SCHEMBL4082007

SCHEMBL4082007

Cc1cc(N(C)C)c2cc(Nc3nc(Nc4ccc5nc(C)cc(N(C)C)c5c4)nc(N4CCN(c5ccncc5)CC4)n3)ccc2n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 9/20 0.59
CYBB P04839 1/20 0.44
NOX5 Q96PH1 1/20 0.44
NOX3 Q9HBY0 1/20 0.44
NOX4 Q9NPH5 1/20 0.44
NOX1 Q9Y5S8 1/20 0.44
MAPT P10636 5/20 0.44
MAPK1 P28482 3/20 0.43
TDP1 Q9NUW8 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
ALOX15 P16050 1/20 0.43
NR4A1 P22736 1/20 0.43
KMT2A Q03164 1/20 0.43
SYK P43405 1/20 0.42
TP53 P04637 2/20 0.41
POLB P06746 1/20 0.41
ADRA2A P08913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4074849 0.87 TERT (0.64) TERTMAPTMEN1KMT2ASYK
SCHEMBL4076582 0.84 TERT (0.59) TERTMAPTMAPK1TDP1KDM4E
SCHEMBL6616885 0.83 TERT (0.58) TERTMAPTADRA2AADRA2BADRA2C
SCHEMBL4076905 0.81 TERT (0.55) TERTMAPTMEN1KMT2A
SCHEMBL4081924 0.79 TERT (0.53) TERTMAPTKDM4EALDH1A1GAA
SCHEMBL4081897 0.78 TERT (0.65) TERTMAPT
SCHEMBL4081851 0.77 TERT (0.64) TERTMAPTALDH1A1
SCHEMBL4076919 0.75 TERT (1.00) TERTMAPTMAPK1MEN1KMT2A
SCHEMBL6614253 0.75 TERT (0.61) TERTMAPTMAPK1TDP1MEN1
SCHEMBL6614255 0.75 TERT (0.61) TERTMAPTMAPK1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887873-B2 Triazine derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2005-05-03 US claimed
US-20030087931-A1 Chemical derivatives and their application as antitelomerease agent AVENTIS PHARMA S.A. (FR) 2003-05-08 US claimed
US-20090226411-A1 CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS AVENTIS PHARMA S.A. (FR) 2009-09-10 US disclosed
US-7482352-B2 Chemical derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2009-01-27 US disclosed
US-6887873-B2 Triazine derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2005-05-03 US disclosed
US-20050070571-A1 Chemical derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2005-03-31 US disclosed
US-20030087931-A1 Chemical derivatives and their application as antitelomerease agent AVENTIS PHARMA S.A. (FR) 2003-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087931-A1 Chemical derivatives and their application as antitelomerease agent DNASE1L3, SERPINB1, BRDT TERT 43/4885CYBB 2184/4885NOX5 2357/4885
US-20090226411-A1 CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS DPYD, NTPCR, NME1 TERT 196/4885CYBB 261/4885NOX5 498/4885
US-20050070571-A1 Chemical derivatives and their application as antitelomerase agents DPYD, NTPCR, NME1 TERT 196/4885CYBB 261/4885NOX5 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.